Verifying…
Home / Registered in Nigeria / Celcarb 450 Injection

Celcarb 450 Injection

NAFDAC Reg. No. A4-5040 · Drug

Registered with NAFDAC. Registration activeAs of 30 October 2026 · synced automatically from official sources.
Product
Celcarb 450 Injection
NAFDAC number
A4-5040
Active ingredient
Carboplatin
Strength
450 mg/45 mL
Form
Concentrate for solution for infusion
Pack size
45 mL x 1's (in vial)
Manufacturer
Not listed
Applicant (holder)
L'PaceMaker Pharmaceuticals Limited
Approved
24 Jun 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
23 Jun 2026
WHO alerts
None found
Community reports
None
Times checked
0

About the medicine: Carboplatin: uses, dosage and brands worldwide

What we found

  • Celcarb 450 Injection is on the NAFDAC register with an active registration (A4-5040). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Celcarb 450 Injection

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Serious warning: Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect. …
Who it is for

INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). …

How to take it and how often
  • NOTE: Aluminium reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminium parts that may come in contact with the drug must not be used for the preparation or administration of carboplatin injection
  • Single Agent Therapy Carboplatin injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m 2 IV on day 1 every 4 weeks (alternatively see Formula Dosing )
  • In general, however, single intermittent courses of carboplatin should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000
  • Combination Therapy with Cyclophosphamide In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: Carboplatin - 300 mg/m 2 IV on day 1 every 4 weeks for 6 cycles (alternatively see Formula Dosing )
  • Cyclophosphamide - 600 mg/m 2 IV on day 1 every 4 weeks for 6 cycles
  • For directions regarding the use and administration of cyclophosphamide please refer to its package insert (See CLINICAL STUDIES .) Intermittent courses of carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000
  • Dose Adjustment Recommendations Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients. …
Talk to a doctor first if
  • Carboplatin injection is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds
  • Carboplatin injection should not be employed in patients with severe bone marrow depression or significant bleeding
Warnings

Bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during carboplatin injection treatment and, when appropriate, until recovery is achieved. Median nadir occurs at day 21 in patients receiving single agent carboplatin. In general, single intermittent courses of carboplatin should not be repeated until leukocyte, neutrophil, and platelet counts have recovered. Since anemia is cumulative, transfusions may be needed during treatment with carboplatin, particularly in patients receiving prolonged therapy. …

Possible side effects

To report SUSPECTED ADVERSE REACTIONS Contact Apotex Corp.at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see CLINICAL STUDIES : Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Comparative Toxicity. ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER * Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by S …

If you take too much

There is no known antidote for carboplatin injection overdosage. The anticipated complications of overdosage would be secondary to bone marrow suppression and/or hepatic toxicity.

How to store it

STORAGE Unopened vials of carboplatin injection are stable to the date indicated on the package when stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. PROTECT FROM LIGHT. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2024-01-07.

Label for carboplatin, the active ingredient registered with NAFDAC.

Check your pack of Celcarb 450 Injection

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · NAFDAC · WHO alerts

About Celcarb 450 Injection

What is in Celcarb 450 Injection?

Celcarb 450 Injection contains Carboplatin (450 mg/45 mL), as concentrate for solution for infusion, according to its NAFDAC registration record.

Is Celcarb 450 Injection registered with NAFDAC?

Yes. Celcarb 450 Injection is listed on the NAFDAC register under registration number A4-5040, and its registration is active as of 30 October 2026.

Has Celcarb 450 Injection been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Celcarb 450 Injection in our automatically synced alert list.

How can I check that my pack of Celcarb 450 Injection is genuine?

Run a free authenticity scan with the NAFDAC number A4-5040, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Celcarb 450 Injection?

Follow your prescription or the leaflet in your pack. The official label says: NOTE: Aluminium reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminium parts that may come in contact with the drug must not be used for the preparation or administration of carboplatin injection. Single Agent Therapy Carboplatin injection, as a single agent, has been shown to be effective in patien…

What is Celcarb 450 Injection used for?

INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cispla (Summarised from the official U.S. FDA label for carboplatin. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Celcarb 450 Injection? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.